Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases

Area of Science:

• Immunology
• Regenerative Medicine
• Rheumatology

Background:

• Rheumatic diseases are chronic, immune-mediated conditions significantly impacting quality of life.
• Current treatments offer symptomatic relief but not cures.
• Mesenchymal stem cells (MSCs) possess immunomodulatory and regenerative properties, presenting a novel therapeutic avenue.

Purpose of the Study:

• To review the clinical progress of Mesenchymal stem cell (MSC) therapy in rheumatic diseases.
• To summarize findings from preclinical and clinical studies.
• To discuss challenges and future directions for MSC therapy in rheumatology.

Main Methods:

• A comprehensive review of preclinical and clinical studies on Mesenchymal stem cell (MSC) therapy was conducted.
• Studies encompassed a wide range of rheumatic diseases.
• Emerging strategies to enhance Mesenchymal stem cell (MSC) efficacy were analyzed.

Main Results:

• Mesenchymal stem cell (MSC) therapy demonstrated potential in reducing inflammation, modulating immune responses, and promoting tissue repair across various rheumatic conditions.
• Clinical trials indicated benefits such as symptom relief and delayed disease progression.
• Variability in treatment response and optimal dosing remain key considerations.

Conclusions:

• Mesenchymal stem cell (MSC) therapy offers potential disease-modifying effects for rheumatic diseases.
• Further large-scale, controlled clinical trials are essential to confirm efficacy and safety.
• Optimized protocols and regulatory frameworks are crucial for clinical integration.